Full text is available at the source.
Abstract
China's market is preparing for the June 2025 approval of the dual agonist mazdutide amid a distinct digital health ecosystem.
- The transition of GLP-1 receptor agonists from diabetes treatments to popular weight loss solutions has sparked widespread information dissemination.
- Previous research has focused primarily on Western digital platforms, highlighting a gap in understanding the Chinese context.
- China faces a unique landscape influenced by an upcoming patent expiration for semaglutide in 2026.
- There is a notable market presence of counterfeit products related to GLP-1 receptor agonists in China.
Simplified